Search results
FDA clears Curio's postpartum depression PDT
NJBIZ· 11 hours agoCurio Digital Therapeutics Inc.’s MamaLife Plus offers a nonpharmaceutical alternative to treating postpartum depression. Princeton-based Curio announced...
Why is a mother’s mental health so important? A doctor explains
KIMT Mason City· 2 days agoToday is World Maternal Mental Health Day, and it’s time to recognize the importance of maternal...
An AI blood test purports to diagnose postpartum depression
Washington Post· 5 days agoPostpartum depression is a leading cause of maternal death, but its diagnosis and treatment is spotty at best, negligent at worst. Now ...
Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN...
The Herald Journal· 3 days agoLipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company, today announced that dosing of subjects has been completed in the pivotal pharmacokinetic (PK) study designed to support a New < ...
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 15 hours agoPhase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for expected completion of double-blind phase in Q3 2024 and of ...
Reunion raises over $100M to build a better psychedelic drug
BioPharma Dive via Yahoo Finance· 2 days agoThe funding will help Reunion pay for a mid-stage study testing its most advanced medicine —...
Whites Not the Predominant Victims of 'Deaths of Despair'
Medscape· 2 days agoDeaths of despair — defined as midlife deaths from suicide, drug overdose, and alcoholic liver...
Reunion Neuroscience Inc. Announces $103 Million Series A Financing Co-Led by MPM BioImpact and Novo...
Benzinga· 2 days agoReunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to pushing the boundaries of neuroscience, today announced the close of a $103 million Series A financing co-led ...
Mental Health Awareness Month kicks off with an urgent report on Black maternal mental health
theGrio· 1 day agoEarlier this year, a study published by JAMA Psychiatry found that 1 in 4 maternal deaths were caused by mental health issues, ranging from suicide to drug overdoses. This ...
MPM BioImpact-owned Reunion raises $103M, one of the largest rounds for a psychedelic biotech
FierceBiotech· 2 days agoIt’s taken decades for psychedelics to regain clinical and regulatory relevance. Reunion Neuroscience has cashed in on a $103 million series A, building on the promise of a phase 2-stage psychedelic ...